Beginning July 1, 2026, the Medicare GLP-1 Bridge Program may allow eligible Medicare Part D patients to access certain obesity-indicated GLP-1 medications, including Foundayo, Wegovy, and certain Zepbound formulations, for no more than $50 per month through December 31, 2027
There is no established therapeutic dose, and claims about metabolic benefits lack robust clinical validation
Small fluctuations are normal
Which Weight-Loss Drugs Are Covered, and What They Cost The Bridge covers GLP-1 medications that are FDA-approved for weight loss
This guide covers every dose level tested in human trials, the exact titration timelines used by researchers, weight loss and liver fat data broken down by milligram, reconstitution and injection protocols, side effect management at each tier, and what the Phase 3 TRIUMPH program tells us about where dosing standards are heading
Comparison table to help weigh trade-offs across treatments #Non-Surgical Radiofrequency Radiofrequency heats the dermis and subdermal layers to contract existing collagen fibers and initiate new collagen production
